The Orion dividend scheduled for October 27, 2026, is €0.90 per share, the second half of the Finnish pharmaceutical company’s €1.80 distribution for the 2025 financial year. The payment follows a decision approved by shareholders on March 24, rather than a newly declared October dividend.
Key Takeaways
- The second instalment is €0.90 per share, with payment scheduled for October 27, 2026.
- Orion set October 20, 2026, as the record date for the second instalment.
- The approved annual dividend totals €1.80 per share and relates to the 2025 financial year.
Table of Contents
Orion dividend dates and payment terms
Orion’s March 2026 dividend resolution sets the second instalment’s record date at October 20 and its payment date at October 27. The record date identifies the shareholders entitled to the distribution; it is distinct from the ex-dividend date used in share trading.
The company declared the payout in euros. The €0.90 October instalment should therefore be distinguished from any dollar-denominated equivalent, which is not specified in the shareholder resolution.
Shareholders also authorised the board to change the second instalment’s record and payment dates if required by changes to Euroclear Finland’s rules, Finnish book-entry regulations or other binding requirements. That authority is a contingency, not an announcement that the dates have changed.
| Item | Details |
|---|---|
| Shareholder approval | March 24, 2026 |
| Financial year covered | January 1–December 31, 2025 |
| First instalment | €0.90 per share |
| First-instalment record date | March 26, 2026 |
| First-instalment scheduled payment | April 2, 2026 |
What the payout establishes—and what it does not
The annual distribution was approved on the basis of Orion’s balance sheet for the year ended December 31, 2025. It confirms the amount and timetable for that dividend, but does not commit the company to a particular distribution for future financial years.
Orion develops, manufactures and markets human and veterinary medicines and active pharmaceutical ingredients. Its portfolio includes proprietary medicines, generics and consumer health products, with pharmaceutical research focused on oncology and pain.
The company reported 2025 net sales of €1.89 billion. That revenue figure provides a measure of business scale, but does not by itself establish dividend coverage: assessing future payments also requires earnings, cash flow and funding needs.
Conclusion
The next scheduled milestone is the October 27, 2026, payment of the €0.90 second instalment, completing Orion’s approved €1.80-per-share dividend for 2025.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
